The ERA Registry Annual Report 2019: summary and age comparisons

Abstract

<jats:title>Abstract</jats:title> <jats:sec> <jats:title>Background</jats:title> <jats:p>Data on renal replacement therapy (RRT) for end-stage renal disease (ESRD) was collected by the European Renal Association (ERA) Registry via national and regional renal registries in Europe and countries bordering the Mediterranean Sea. This paper provides a summary of the 2019 ERA Registry Annual Report, including data from 34 countries and additional age comparisons.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>Individual patient data for 2019 was provided by 35 registries and aggregated data by 17 registries. Using this data, the incidence and prevalence of RRT, the kidney transplantation activity and the survival probabilities were calculated.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>In 2019, a general population of 680.8 million people was covered by the ERA Registry. Overall, the incidence of RRT was 132 per million population (p.m.p.). Of these patients, 62% were men, 54% were ≥ 65 years of age, 21% had diabetes mellitus as primary renal disease, and 84% had haemodialysis (HD), 11% had peritoneal dialysis (PD) and 5% had pre-emptive kidney transplantation as initial treatment modality. The overall prevalence of RRT on 31 December 2019 was 893 p.m.p., with 58% of patients on HD, 5% on PD, and 37% living with a kidney transplant. The overall kidney transplant rate was 35 p.m.p. and 29% of the kidney grafts were from a living donor. The unadjusted 5-year survival probability was 42.3% for patients commencing dialysis, 86.6% for recipients of deceased donor grafts and 94.4% for recipients of living donor grafts in the period 2010–2014. When comparing age categories, there were substantial differences in the distribution of primary renal disease, treatment modality, kidney donor type, and in the survival probabilities.</jats:p> </jats:sec>